UnitedHealth Group Inc vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? UnitedHealth Group Inc trades at $397.51 (market cap $339.08B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: UnitedHealth Group Inc is far larger — about 97.4× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and UnitedHealth Group Inc pays the higher dividend (2.46%). Which is the better fit depends on your goals — on Pluang, investors hold UnitedHealth Group Inc for 98 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| UNH | ZGN | |
|---|---|---|
Market Cap | $339.08B | $3.48B |
Volume | 12,648,635 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $436.35 | $15.25 |
52-Week Low | $259.02 | $8.69 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $380.94B | $4.43B |
Dividend Yield | 2.46% | 1.06% |
Signals from Pluang's Aura AI — not financial advice
UnitedHealth Group (UNH) trades at $378.52, down 0.21% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats in recent quarters, including Q3 2026 EPS of $4.69 beating expectations of $4.14. Revenue growth remains solid at $447.57B for 2025, though net margins have compressed to 3.14%. Recent developments include strategic moves with TPG for WellMed operations and continued AI investments in Optum Insight.
UNH presents a compelling investment case with 82.7% analyst buy ratings and a $470.11 consensus price target representing 24% upside. The company's Medicare Advantage strength and Optum improvements support growth, though regulatory scrutiny and medical cost pressures remain key risks. Strong institutional ownership and Michael Burry's recent call option position signal confidence in the turnaround story.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →